Webinar preview
Over the past decade, oncology care has undergone a remarkable transformation, driven by the advent of precision medicine. This revolution has been fueled by a deeper understanding of cancer’s biological underpinnings, leading to the development of biomarker-driven therapies. These therapies, tailored to individual patients’ genetic and molecular profiles, promise improved treatment outcomes and reduced side effects.
In this webinar, the expert speaker will explore the evolving role of diagnostic labs in the landscape of biomarker-driven oncology therapies. Traditionally, diagnostic labs have been key players in the healthcare continuum, primarily providing essential diagnostic services. However, with the rise of precision medicine, these labs are now at the forefront, acting as strategic partners in drug development and clinical implementation.
The speaker will explore:
- The Rise of Biomarker-Driven Therapies: The attendees will get to understand how biomarkers are revolutionizing cancer treatment by offering targeted therapies that align with specific cancer subtypes. They will also learn about the pivotal role of biomarkers like human epidermal growth factor receptor 2 (HER2) in breast cancer and their impact on therapy development
- Shifting Dynamics in Drug Development: The attendees will get to discover how biomarker-driven approaches are streamlining drug development, reducing time to approval and increasing the success rates of new therapies. They will also get to explore the collaborative efforts between pharmaceutical companies and diagnostic labs that are expediting this process
- The Changing Role of Diagnostic Labs: The attendees will also get to examine how diagnostic labs have transitioned from service providers to proactive partners in oncology care. They will also get to learn about their early involvement in clinical trials and the development of companion diagnostics, ensuring accurate and timely treatment allocation
This webinar will highlight the collaborative synergy among pharmaceutical companies, diagnostic labs and healthcare providers, emphasizing the integrated approach necessary for advancing patient care. The speaker will discuss real-world examples and case studies, providing attendees with a comprehensive understanding of how precision medicine is reshaping the future of oncology. He will offer valuable insights into the dynamic role of diagnostic labs in the era of precision medicine and explore the promises and challenges that lie ahead on collectively driving better outcomes for cancer patients.
Who should attend?
This webinar is ideal for professionals in the pharmaceutical industry, particularly those involved in oncology drug development and precision medicine. Key attendees include:
- Pharma industry professionals focused on oncology and precision medicine drug development
- Clinical researchers and scientists engaged in biomarker research
- Decision-makers and strategists seeking to enhance their understanding of biomarker-driven therapies and their impact on drug development
What you will learn
Attendees will learn about:
- The pivotal role of biomarkers in developing targeted cancer therapies
- How biomarker-driven approaches are streamlining the drug development process
- The evolving responsibilities of diagnostic labs in precision oncology
- Real-world examples of collaborative efforts between pharmaceutical companies and diagnostic labs
Your Privacy Choices